Treatment of parkinsons disease with stem cells
,1,* Hamidreza raeespour
1. Gene pajoohane Ebnesina genetic research Laboratory, keshavarz Boulvevard, Tehran, Iran
2. Gene pajoohane Ebnesina genetic research Laboratory, keshavarz Boulvevard, Tehran, Iran
parkinsons disease(pd) causes problems in motor function and cell death. the second most common illness after alzheimers disease. it has not yet been determined that mutations in a number of specific genes, such as sinineol (snca), and repetitions of leucine-rich kinase 2, play a role in increasing pds sensitivity. significant signs of pd as a result of dopamineric in the motor system (da), degeneration of the neural cells is an underlying mechanism, but the lysis of the cell is still unknown, the oxidative stress of the protein increases and aggravates many problems. the mitochondrial function affects the pathogenesis of pd. no therapies for pd have yet been found. treatments such as l 3,4-dihydroxyphenylalanine (l-dopa) and dopamine agonists have been shown to affect motor impairment. these treatments prevent certain pd symptoms and disease progression, and protect da cells and nerve cells during pd progression. the referral of immature neurons da has been studied in pd patients since the late 1980s. studies have shown that adscs can cure brain damage from a variety of neurological and neurological diseases and can reduce the symptoms of brain disease directly by the cell, and the replacement is indirectly transmitted by the transfer of certain specific factors. adscs play the role of neuroprotection and neuronal decline. apoptosis. the diffraction factors released by adscs reduce the proteins accumulation in patients with alzheimers disease. different pd treatments are available today, including a levodopa drug and deep brain stimulation. 3-4 patients respond to levodopa, and are useful but in some cases minimized.
1- we performed a search in pubmed with the following mesh terms: parkinsons disease, fatty stem cells, n-butylidenephthalide, levodopa, deep-brain, pluripotent stem cells
2- the search was narrowed to original articles published in english.
3- we restrict our research to major journal in the field of stem cell research
We examined the therapeutic effects of bp treatment. adscs in a mptp-based mouse model of pd an analysis of animal animals with different concentrations of bp is important for determining the best treatment. the conditions of the adscs in bp forserially diluted for culture were analyzed 24 or 48 hours later, and stability was then analyzed. adsc sustainability decreases when the concentration of bp / mg / ml is reduced to 24 hours. long-term treatment (48 hours) indicates a further reduction in animals at high and stable concentrations of 40 mg / ml or less. these results indicated that high bp concentrations had a negative effect on cell growth and survival, but bp was used at a concentration of 40 mg / ml or less. we reviewed the possibility of adsc linking. adsc with or without bm 20mg / ml was transferred to the pd brain. injection on the third day of induction of pd caused impairment in motor skills, balance and coordination in the b6 mouse. stem cell stem cells are mature and easy to use. initially, viral transcription factors enter the cell and lead to increased ipscs treatment for inadequate treatment due to tumorigenicity. these treatments are still performed in humans in the inhuman models of ipscs that are capable of delivering performance to parkinsons damaged areas. ipscs can be a progressive loss of dp neurons compared to the parkins gene model.
Neurological symptoms.in this bp prevention study, the adsc connection improves pds motor symptoms and protects dopamine neurons in the pd model. other treatment options for patients with pd include levodopa and deep- brain stimulation, but for people with diabetes it is not a type of panasonic and only reduces symptoms. stem cell techniques suggest that treatment with neural stem cells has been created and it is hoped to be used as a treatment for pd in the future, because its function is to screen and model the drug and make it a substitute for cell therapy.
Parkinsons disease, fatty stem cells, n-butylidenephthalide, levodopa, deep-brain, pluripotent stem